Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;9(4):2157-2160.
doi: 10.21037/tcr.2020.02.75.

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer

Gerhard Hamilton  1
Affiliations
Editorial

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer

Gerhard Hamilton. Transl Cancer Res. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.02.75). The author has no conflicts of interest to declare.

Comment on

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Golan T, et al. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157963 Free PMC article. Clinical Trial.

References

    1. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9. 10.1038/nm0901-987 - DOI - PubMed
    1. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014;32:1309-16. 10.1200/JCO.2013.51.4240 - DOI - PMC - PubMed
    1. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302-8. 10.1200/JCO.2013.51.4489 - DOI - PubMed
    1. Bamias A, Gibbs E, Khoon Lee C, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol 2017;28:1842-8. 10.1093/annonc/mdx228 - DOI - PubMed
    1. Rossi L, Verrico M, Zaccarelli E, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget 2017;8:12389-405. 10.18632/oncotarget.13310 - DOI - PMC - PubMed